Stallergenes Greer and Anergis Report Successful Preclinical Study Results With COP-virosomes as Second-generation Allergen Immunotherapy
(WorldNews Business)

LONDON, UK & EPALINGES, Switzerland--(BUSINESS WIRE)--May 28, 2020-- Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, today announced the results of a joint research study evaluating the effects of second-generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005066/en/ COP-Virosomes, COP alone and virosomes alone were...